Breaking News
October 22, 2018 - The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award
October 22, 2018 - Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients
October 22, 2018 - Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC
October 22, 2018 - Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis
October 22, 2018 - Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients
October 22, 2018 - Prostate radiotherapy improves survival in men with low burden of metastatic disease
October 22, 2018 - Free phone app helps low-income obese patients to lose weight
October 22, 2018 - Compression Collar May Protect Brain of Female Soccer Players
October 22, 2018 - Technique visualizes neuron communication
October 22, 2018 - Advancement in medical imaging methods for health care
October 22, 2018 - Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis
October 22, 2018 - Immunotherapy increases survival in some patients with metastatic triple negative breast cancer
October 22, 2018 - Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma
October 22, 2018 - LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer
October 22, 2018 - Brainlab unveils ExacTrac Dynamic at ASTRO meeting in San Antonio, Texas
October 22, 2018 - Not exercising is worse than smoking, diabetes or heart disease finds study
October 22, 2018 - Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer
October 22, 2018 - Map of Mouse Hippocampus Could Be Weapon Against Alzheimer’s
October 22, 2018 - Psychotropic polypharmacy is common in Alzheimer’s disease
October 22, 2018 - Texas A&M and UTA establish Texas Genomics Core Alliance
October 22, 2018 - Analyzing mouse’s potential as animal model of decision-making
October 22, 2018 - Radiotherapy can prolong survival in prostate cancer
October 22, 2018 - A genetic mutation involved in relapse
October 21, 2018 - Report reveals growing impact of cannabis on young people
October 21, 2018 - NSF awards $5 million grant to help scientists magnify societal impact of research
October 21, 2018 - Fertility Rates Down for Each Urbanization Level 2007 to 2017
October 21, 2018 - Genetically engineered 3-D human muscle transplant in a murine model
October 21, 2018 - Moms’ tight work schedules may affect their children’s sleep
October 21, 2018 - AHA: No Direct Link Between Preeclampsia and Cognitive Impairment, Study Finds
October 21, 2018 - Weight loss success linked with active self-control regions of the brain
October 21, 2018 - Scripps researchers successfully test potential new smoking-cessation treatment in rodents
October 21, 2018 - More accurate and less stressful way to measure a baby’s heartbeat
October 21, 2018 - Researchers show better cardiorespiratory fitness leads to longer life
October 21, 2018 - Healthy candies for diabetic patients
October 21, 2018 - Environment impact of microplastics remains unclear
October 21, 2018 - Antibiotics for appendicitis? Surgery often not needed
October 21, 2018 - AHA and AMA recognize more than 800 medical practices, health systems for blood pressure control
October 21, 2018 - Scientists obtain clearest ever image of Ebola virus protein
October 21, 2018 - Study reveals connection between two proteins known to be hyperactive in cancer
October 21, 2018 - Gabapentin Beats Pregabalin for Chronic Sciatica
October 21, 2018 - Cosmetic surgeons offering incomplete information for breast augmentation customers
October 21, 2018 - Chronic sleep disruption in early adult life accelerates AD-related tau pathology
October 21, 2018 - Take 10 for Mindfulness – Drugs.com MedNews
October 21, 2018 - Length of breathing disruption in OSA may be better predictor of mortality risk
October 21, 2018 - ApoE4 gene linked with chronic inflammation increases risk for Alzheimer’s disease
October 21, 2018 - Mother-daughter conflict associated with suicide risk in abused adolescent girls
October 21, 2018 - Scientists molding bacteria into unnatural shapes
October 21, 2018 - High diet quality associated with lower risk of death in colorectal cancer patients
October 21, 2018 - Discharged mental health patients ‘at greater risk of dying’
October 21, 2018 - Research provides insight into neurobiology of aggression and bullying
October 21, 2018 - As billions in tax dollars flow to private Medicaid plans, Who’s minding the store?
October 21, 2018 - Neuroscientists identify brain region that appears to be related to food preference decisions
October 21, 2018 - Deaths related to air pollution in the U.S. decreased by 47% between 1990 and 2010
October 21, 2018 - Study shows correlation between spatial memory and the sense of smell
October 21, 2018 - Increased cardiorespiratory fitness associated with reduced long-term mortality
October 21, 2018 - IU researchers receive $1.55 million from NIH to improve chronic-disease management
October 21, 2018 - Income and wealth affect the mental health of Australians, study shows
October 21, 2018 - Patients with hypertension and psoriasis more often require cardiovascular interventions
October 20, 2018 - Leading hip-hop videos depict use of tobacco and marijuana products, study finds
October 20, 2018 - Dose Range of IV Ketamine for Adjunct Tx of Depression Tested
October 20, 2018 - Infants can distinguish between leaders and bullies, study finds
October 20, 2018 - Mad Cow disease found on Aberdeenshire farm
October 20, 2018 - Study identifies factors associated with prescription opioid misuse among students
October 20, 2018 - Scientists uncover key regulator of mTORC1 in cancer growth
October 20, 2018 - Pounds Regained After Weight-Loss Op Can Tell Your Doc a Lot
October 20, 2018 - Sending parents letters to fight childhood obesity doesn’t work
October 20, 2018 - Supervised aerobic exercise can support major depression treatment
October 20, 2018 - Mindfulness-based program effective for reducing stress in infertile women
October 20, 2018 - Molecule capable of halting and reverting neurodegeneration caused by Parkinson’s disease identified
October 20, 2018 - Midazolam-mediated alterations of PER2 expression may have functional consequences during myocardial ischemia
October 20, 2018 - Sweat bees are ideal for studying the genes underlying social behavior
October 20, 2018 - Weight loss success associated with brain areas involved in self-control
October 20, 2018 - KHN’s ‘What the Health?’ Republicans’ preexisting political problem
October 20, 2018 - Research provides a more complete picture of suffering caused by terrorist attacks
October 20, 2018 - Eradicating Helicobacter pylori infections may be a key treatment for Parkinson’s disease
October 20, 2018 - Breast Cancer as a Dynamic Disease
October 20, 2018 - University of Pittsburgh wins NSF grant for big data research to prevent complications from anesthesia
October 20, 2018 - Skin-to-skin contact may promote attachment between parents and preterm infants
October 20, 2018 - Recommendations Developed to Verify NGT Placement in Children
October 20, 2018 - Weight loss can be boosted fivefold thanks to novel mental imagery technique
St. Jude gene therapy offers hope for infants with ‘bubble boy’ disease

St. Jude gene therapy offers hope for infants with ‘bubble boy’ disease

image_pdfDownload PDFimage_print

Early evidence suggests that gene therapy developed at St. Jude Children’s Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder. Preliminary results from the ongoing, multicenter study were included in the press program here today at the 59th annual meeting of the American Society of Hematology.St.

Approximately four months after treatment, five of the seven patients enrolled in the St. Jude clinical trial had immune systems for the first time. The patients no longer require protective isolation. Four patients have started making serum immunoglobulins (antibodies) for the first time. One has stopped monthly immunoglobulin supplementation and recently received his first set of vaccinations.

“These results are an exciting early indication that this gene therapy is well tolerated and effective in infants as young as 2 months old with this devastating inherited immune disorder,” said Ewelina Mamcarz, M.D., an assistant member of the St. Jude Department of Bone Marrow Transplantation and Cellular Therapy. She spoke at the press conference and will present the findings Sunday, Dec. 10, at 4:30 p.m.

Immune protection will likely return to the last patient. There is evidence that the seventh patient, who joined the study six weeks ago, now carries the vector in his immune cells. No serious or unexpected treatment-related complications have been reported.

The results are the first involving infants with XSCID treated with the St. Jude lentiviral vector. Researchers previously reported promising results in adolescents and young adults with XSCID who were treated with the St. Jude vector and low-dose chemotherapy after bone marrow transplantation failed to restore adequate immune protection.

The patients in this study were between the ages of 2 and 13 months and born with a disorder caused by a mutation in the IL2RG gene. The mutation primarily affects boys and leaves them with little or no immune protection. The disorder is also known as “bubble boy” disease, a reference to the measures used to protect patients from infections and other threats. Untreated, individuals usually die of overwhelming infections within months.

Currently, transplantation with a tissue-matched sibling donor is the standard treatment for XSCID. More than 80 percent of XSCID patients, including the infants in this study, do not have matched sibling donors. These patients must rely on unrelated donors or parent donors, who are partial genetic matches. Such transplants are less likely to fully restore immune function and are associated with potentially severe treatment-related complications.

In response, St. Jude researchers have re-engineered a lentivirus to function as a vector to ferry a normal copy of IL2RG into the patients’ hematopoietic stem cells. The vector includes novel features to enhance safety and effectiveness. The features include genetic insulators to block activation of genes adjacent to the IL2RG DNA insertion site. The design aims to ensure gene therapy will not lead to leukemia by inadvertently activating an oncogene in the patient’s hematopoietic stem cells.

The treatment involves removing the patient’s bone marrow and letting the hematopoietic stem cells incubate with the lentiviral vector carrying the normal gene. The stem cells are then processed and returned to the patient via transfusion. Prior to transfusion, patients receive low-dose chemotherapy with the drug busulfan. Unlike the prior studies, the level of busulfan in the patient’s blood is pharmacologically targeted to avoid variability in blood levels and improve safety. The chemotherapy is designed to make space in the bone marrow for the gene-corrected hematopoietic stem cells to settle in and start working.

“These early results in infants reinforce hope that gene therapy will prove to be safe and effective at restoring immune function early in life,” said Brian Sorrentino, M.D., a member of the St. Jude Department of Hematology, who leads this study with Mamcarz.

Following gene therapy, levels of T, B and natural killer cells rose to near normal levels in five of the first six patients who enrolled in the study. The vast majority of the immune cells, including 100 percent of the T and natural killer cells, carried the normal gene that was carried in the lentiviral vector. 60 to 80 percent of the B cells also carried the normal gene. Previous gene therapy for XSCID did not lead to such high levels of genetic correction in all immune cell types.

In three of the five patients, 50 percent or more of the hematopoietic stem cells also carried the normal gene. “This suggests these patients will likely enjoy life-long immune protection without exposure to high-dose chemotherapy,” Mamcarz said. This level of bone marrow stem cell correction has not been achieved in prior gene therapy studies in XSCID infants.

The sixth patient included in the report received a booster dose of gene-corrected blood stem cells. Laboratory tests indicate T cells, including T cells with the correct gene, have begun to increase. “This was a complex patient,” Mamcarz said. The patient was being treated for severe neutropenia and a viral infection when he joined the study. In addition, maternal T cells had engrafted in his bone marrow, complicating efforts to restore his own genetically corrected blood stem cells to his bone marrow.

Source:

https://www.stjude.org/media-resources/news-releases/2017-medicine-science-news/gene-therapy-improves-immunity-in-babies-with-bubble-boy-disease.html

Tagged with:

About author

Related Articles